Pliant Therapeutics Inc. (PLRX): Price and Financial Metrics

Pliant Therapeutics Inc. (PLRX): $15.01

0.93 (-5.83%)

POWR Rating

Component Grades








Add PLRX to Watchlist
Sign Up

Industry: Biotech




#354 of 359

in industry

PLRX Price/Volume Stats

Current price $15.01 52-week high $36.64
Prev. close $15.94 52-week low $14.98
Day low $14.98 Volume 523,600
Day high $15.97 Avg. volume 789,293
50-day MA $17.26 Dividend yield N/A
200-day MA $22.90 Market Cap 898.11M

PLRX Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where PLRX ranks best; there it ranks ahead of 42.4% of US stocks.
  • The strongest trend for PLRX is in Growth, which has been heading down over the past 179 days.
  • PLRX's current lowest rank is in the Stability metric (where it is better than 6.73% of US stocks).

PLRX Stock Summary

  • With a price/sales ratio of 195.08, PLIANT THERAPEUTICS INC has a higher such ratio than 98.42% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for PLIANT THERAPEUTICS INC; that's greater than it is for just 8.73% of US stocks.
  • As for revenue growth, note that PLRX's revenue has grown -48.95% over the past 12 months; that beats the revenue growth of merely 5.34% of US companies in our set.
  • Stocks that are quantitatively similar to PLRX, based on their financial statements, market capitalization, and price volatility, are JANX, MRTX, LYEL, KRON, and ORMP.
  • PLRX's SEC filings can be seen here. And to visit PLIANT THERAPEUTICS INC's official web site, go to

PLRX Valuation Summary

  • PLRX's EV/EBIT ratio is -6.6; this is 153.23% lower than that of the median Healthcare stock.
  • Over the past 40 months, PLRX's price/sales ratio has gone up 182.3.

Below are key valuation metrics over time for PLRX.

Stock Date P/S P/B P/E EV/EBIT
PLRX 2023-09-18 195.1 1.8 -6.8 -6.6
PLRX 2023-09-15 190.6 1.8 -6.6 -6.4
PLRX 2023-09-14 192.6 1.8 -6.7 -6.5
PLRX 2023-09-13 195.8 1.8 -6.8 -6.6
PLRX 2023-09-12 197.7 1.9 -6.9 -6.7
PLRX 2023-09-11 195.4 1.8 -6.8 -6.6

PLRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PLRX has a Quality Grade of D, ranking ahead of 14.66% of graded US stocks.
  • PLRX's asset turnover comes in at 0.047 -- ranking 325th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows PLRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.047 1 -0.360
2021-03-31 0.050 1 -0.363
2020-12-31 0.149 1 -0.245

PLRX Price Target

For more insight on analysts targets of PLRX, see our PLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.33 Average Broker Recommendation 1.38 (Strong Buy)

Pliant Therapeutics Inc. (PLRX) Company Bio

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

PLRX Latest News Stream

Event/Time News Detail
Loading, please wait...

PLRX Latest Social Stream

Loading social stream, please wait...

View Full PLRX Social Stream

Latest PLRX News From Around the Web

Below are the latest news stories about PLIANT THERAPEUTICS INC that investors may wish to consider to help them evaluate PLRX as an investment opportunity.

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer. Ms. Kuo will oversee all aspects of the Company’s nonclinical and clinical development activities. “Minnie is an accomplished biopharmaceutical leader who brings extensive clinical develo

Yahoo | September 15, 2023

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following September investor conferences. Citi 18th Annual BioPharma Conference Members of senior management will meet with investors on Wednesday, September 6, 2023.H.C. Wainwright 25th Annual Global Investment Conference Bernard

Yahoo | August 30, 2023

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced three upcoming presentations at the European Respiratory Society (ERS) International Congress 2023. The congress will take place in Milan, Italy from September 9, 2023 to September 13, 2023. Oral and Poster Presentation Title: Dual αVβ6/αVβ1 integrin i

Yahoo | August 28, 2023

15 Most Shorted Stocks That Are Loved By Analysts

In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts. If you want to skip our introduction to short selling, then jump ahead to 5 Most Shorted Stocks That Are Loved By Analysts. Short selling is a tricky game. Rapid share price appreciations can stretch a […]

Yahoo | August 28, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 4.11% and 77.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2023

Read More 'PLRX' Stories Here

PLRX Price Returns

1-mo -9.14%
3-mo -27.98%
6-mo -42.99%
1-year -24.31%
3-year -31.99%
5-year N/A
YTD -22.35%
2022 43.19%
2021 -40.58%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!